Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Bullboard Posts
Post by Trademark11on Sep 20, 2018 6:03am
302 Views
Post# 28653071

EBITDA increase of $1 million

EBITDA increase of $1 millionDoug Cooper at Beacon has the run rate for F19 Ebitda at $14.6 million as of August's update.  Adding $1 million onto the operating cash flow through this aquisition represents an increase in EBITDA of 6.7%.  This means, according to my calculations, that PHM is presently trading at 3.2x F19 EBITDA. In the update he raised the 12 month target to $0.45 based on the industry average of 12 x EBITDA.  Presently with this run rate and not taking into account that they seem to be growing organically at a higher rate than the industry, I come to a 12month target of $0.4875....

A 4-BAGGER IN THE MAKING

Technically, even though some here discount its validity (to their own peril), the sp may be attempting to complete a continuation triangle initiated on May 3, 2018 and has recently had 2 closes above the 200 dMA....something that it hasn't done since November 27, 2017.  Whether or not the triangle turns out to be bullish or bearish is yet to be seen, but the fundamentals are supporting to the upside IMO.  Personally I am watching very closely for 3 days of closes above $.0.145 as the bullish indicator.  Multiple closes below $0.115 would refute this thesis IMO
Bullboard Posts